Molecular data
| Molecular formula | BLEND |
|---|---|
| Physical form | Lyophilized Powder (co-lyophilized blend) |
| Available sizes | 10mg |
How it works
CJC-1295: GHRH Receptor Activation
CJC-1295 (Modified GRF 1-29) is the GHRH receptor agonist component. It binds GHRH-R on pituitary somatotrophs, stimulating cAMP production and GH synthesis. The four DPP-IV-resistant amino acid substitutions extend bioavailability to ~30 minutes, enabling a sustained window of GHRH-R activation per dose.
- GHRH-R agonism — cAMP-mediated GH synthesis
- ~30-minute half-life for time-matched dosing
- Cortisol, thyroid, prolactin unaffected
Ipamorelin: Ghrelin Receptor Activation
Ipamorelin is the GHSR-1a (ghrelin receptor) agonist component. It binds a distinct receptor population on somatotrophs via a phospholipase C / IP3 intracellular pathway — separate from the cAMP route used by GHRH. This complementary signaling allows both pathways to be active simultaneously without receptor competition.
- GHSR-1a agonism — PLC/IP3 intracellular pathway
- No cortisol, ACTH, or prolactin co-secretion
- ~2-hour half-life — pulsatile GH release
Dual-Pathway Synergistic GH Amplification
When GHRH-R and GHSR-1a are activated simultaneously, GH pulse amplitude exceeds what either compound produces alone. Preclinical data show this additive-to-synergistic interaction: each pathway potentiates the other's pituitary response, producing larger GH pulses without proportionally increasing side effects.
- Additive GH pulse amplitude vs either alone
- Somatostatin suppression potentiated by GHSR agonism
- Physiologic pulsatile pattern preserved
What the research shows
Dual-Pathway GH Stimulation
Simultaneous GHRH-R and GHSR-1a activation produces additive GH pulse amplification — a model for studying maximal pituitary GH secretory capacity while maintaining physiologic pulse architecture.
Raun et al. 1998
Physiologic Secretion Patterns
The short half-lives of both components (~30 min for CJC-1295; ~2 hr for ipamorelin) preserve pulsatile GH release — enabling research into GH pulse physiology without continuous baseline elevation.
Frieboes et al. 2004
Selectivity vs GHRP-6 Blends
CJC-1295/Ipamorelin is studied as a high-selectivity alternative to CJC-1295/GHRP-6 combinations — preserving GH stimulation amplitude while eliminating cortisol and prolactin co-secretion associated with GHRP-6.
Raun et al. 1998
Complementary Signaling Pathways
GHRH-R signals via cAMP/PKA while GHSR-1a signals via PLC/IP3 — distinct second messenger cascades that do not compete. This orthogonal mechanism makes the combination a research model for studying receptor cross-talk in neuroendocrine signaling.
Kojima & Kangawa 2001
Specification
| Strength | 10mg |
|---|---|
| molecular_formula | BLEND |
| Molecular Weight | N/A (Blend) |
| Purity | >99% (HPLC) |
| Form | Lyophilized Powder |
| Blend Components | CJC-1295 (Modified GRF 1-29) + Ipamorelin |
| CJC-1295 Type | GHRH analog — GHRH-R agonist (no DAC modification) |
| Ipamorelin Type | Pentapeptide GH secretagogue — GHSR-1a agonist |
| CJC-1295 MW | 3,367.9 g/mol |
| Ipamorelin MW | 711.9 g/mol |
| CJC Half-Life | ~20–30 minutes |
| Ipamorelin Half-Life | ~2 hours |
| Form | Lyophilized powder (co-lyophilized blend) |
| Purity | ≥99% each component (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (lyophilized) | -20°C for up to 24 months |
| Storage (reconstituted) | 2–8°C, use within 30 days |
| Solubility | Bacteriostatic water for reconstitution |
| COA | Included with every order |
| Appearance | White to off-white powder |
Frequently asked questions
What is the CJC-1295 / Ipamorelin blend and why are these two combined?
The CJC-1295/Ipamorelin blend combines two peptides that stimulate pituitary GH release through distinct, complementary receptor systems. CJC-1295 (Modified GRF 1-29) activates GHRH receptors (GHRH-R) via the cAMP/PKA intracellular pathway. Ipamorelin activates GHSR-1a (ghrelin receptors) via the PLC/IP3 pathway. Because these are separate receptor populations using different second messenger systems, simultaneous activation produces additive-to-synergistic GH pulse amplification without receptor competition or off-target hormone effects.
Why is ipamorelin preferred over GHRP-6 in combination with CJC-1295?
Both ipamorelin and GHRP-6 are GHSR-1a agonists, but ipamorelin is significantly more selective. GHRP-6 co-elevates cortisol, ACTH, and prolactin — stress and pituitary hormones that confound research readouts. Ipamorelin produces comparable GH stimulation without these side effects (Raun et al. 1998). For research protocols requiring isolated study of GH/IGF-1 axis effects, the CJC-1295/Ipamorelin combination provides cleaner data by eliminating cortisol and prolactin as variables.
What does "pulsatile GH secretion" mean and why is it important?
Pulsatile GH secretion means GH is released in discrete bursts rather than a steady continuous stream. Endogenously, this occurs 6–12 times per day, with the largest pulses during slow-wave sleep. The pulsatile pattern is important because GH receptor sensitivity, downstream IGF-1 production, and metabolic effects all depend on the pulse amplitude and inter-pulse interval. CJC-1295/Ipamorelin preserves this pulsatile architecture (due to short half-lives) — making it a tool for studying GH pulse physiology rather than pharmacological continuous GH replacement.
Is there published research specifically on the CJC-1295/Ipamorelin combination?
Direct combination studies have not been published in the peer-reviewed literature. The scientific rationale for the combination is derived from: (1) Ipamorelin pharmacology demonstrating GHSR-1a selective GH stimulation (Raun et al. 1998); (2) CJC-1295 clinical trial data showing GHRH-R-mediated GH/IGF-1 elevation (Teichman et al. JCEM 2006); and (3) preclinical studies demonstrating additive GH responses when GHRH and GH secretagogues are co-administered, reviewed by Muller et al. (1999).
Is the CJC-1295 / Ipamorelin blend FDA-approved?
No. Neither CJC-1295 without DAC nor ipamorelin is FDA-approved for any indication, and the combination has no regulatory approval. Both are research compounds classified as not intended for human therapeutic use. This blend is sold exclusively for in vitro research purposes.
How should the CJC-1295 / Ipamorelin blend be stored?
The lyophilized powder blend should be stored at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Both components maintain stability in lyophilized form; CJC-1295 is relatively more sensitive to DPP-IV degradation in solution due to the absence of albumin binding.
Literature
- PubMed Ipamorelin, the first selective growth hormone secretagogue
- PubMed Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults
- PubMed Growth hormone secretagogues — mechanisms of action and synergy with GHRH
- PubMed Ghrelin and the GH secretagogue receptor: from discovery to therapeutic use
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.